Source: Annual Congress 2009 - Treatment of lung cancer
Disease area: Thoracic oncology

Abstract

Objective: The aim of this study was to determine the influence of gender, age, smoking, performance status (ECOG), histology and stage on survival in the first year of treatment in non-small cell lung cancer (NSCLC) patients.
Method: The study was retrospective, conducted at the Institute for Pulmonary Diseases of Vojvodina, Serbia. Patients diagnosed with NSCLC in year 2007 entered the study. Mono and multivariate analysis and proportional frequency of specific characteristics were performed to determine which characteristics have influence on first year survival in NSCLC patients.
Results: The study included 869 NSCLC patients, 671 males and 198 females. Most of the patients were aged 51-60 years (38.09%). Majority of patients were smokers (82.51%), with ECOG 1 performance status (50.98%); the most common type of lung cancer was squamous-cell (46.61%), while the most common stage was IIIB (39.70%). The characteristics found to significantly improve survival are ECOG 0 and 1 (p=0.00), squamous-cell lung cancer (p=0.01) and stage I and II (p=0.00). Predictors of poor survival in first year are found to be age over 71 years (p=0.04), ECOG 2 and 3 (p=0.00), adenocarcinoma (p=0.03) and stage IIIB and IV (p=0.00).
Conclusion: The results of this trial suggest that ECOG 0 and 1, stage I and II, and squamous histology may be the factors favorable for better survival in first year. Factors contributing to poor survival could be older age, ECOG 2 and 3, adenocarcinoma and stage IIIB and IV. Smoking was not derived as a predictor, probably because majority of our patients were smokers. Larger studies must follow to confirm and define these predictors.

Rating:

Share or cite this content

Citations should be made in the following way:
T. Sarcev, J. Stanic, A. Andjelkovic, B. Zaric (Sremska Kamenica, Republic Of Serbia). Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients. Eur Respir J 2009; 34: Suppl. 53, 2646

Member's Comments

No comment yet.

Related content which might interest you: Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient Source: Eur Respir J 2015; 46: 280-282 Year: 2015 Time trends in treatment and survival of non-small cell lung cancer in The Netherlands Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010 Effects of prognostic factors on survival of the patients of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005 Clinical factors of long-term survival in patients with advanced lung cancer Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007 Prognostic factors affecting survival in advanced non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004 Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer Source: Eur Respir J, 51 (5) 1702431; 10.1183/13993003.02431-2017 Year: 2018 Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 Effect of comorbidity on the prognosis of non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006 Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 Early recurrence in complete resected non-small cell lung cancer patients Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017 Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008 Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy Source: Eur Respir Rev 2013; 22: 565-576 Year: 2013 The correlation between clinical and pathomorphological impacts of induction chemotherapy and long-term results of multimodality treatment for IIIA stage non-small cell lung cancer Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007